Meet Central Florida Regional Leader: Juli Millas September 2, 2020 by Kylie Karley Juli Millas is an FSGS patient living in the Central Florida area, who was first diagnosed in July 2002. She has built a strong sense of community within her region and is passionate about supporting others with rare protein-spilling kidney diseases. While she typically meets up with other local families at Tampa Pig Jig every year, she’s getting creative and adapting due to the pandemic cancelling the 2020 event. Learn what she has planned instead for her community! What’s your personal connection to NephCure? I discovered NephCure about seven years ago after attending the Tampa Pig Jig. As an FSGS patient, I couldn’t believe it; I had found a community of people just like me that I had no idea existed! It was nirvana! I found my tribe! When NephCure was looking for volunteers, I knew I had to get involved and I jumped at the opportunity to be a part of them. Being the patient engagement and support volunteer, as well as the regional leader, for Central Florida brings me such joy, pride and satisfaction. I know that I’m a part of something that is making a difference for Nephrotic Syndrome patients. Why do you volunteer with NephCure? Juli and other Nephrotic Syndrome families at Tampa Pig Jig. I’m committed to volunteering for NephCure because I don’t want anyone with Nephrotic Syndrome to ever feel as desperate, lonely, and isolated as I did when I first got sick. I want everyone to know that NephCure is here for them with information, support, and most of all community! What projects are you working on right now? The two projects I’m currently working on came to fruition because of the Tampa Pig Jig being cancelled due to COVID-19 this year. Pig Jig is a huge fundraiser for NephCure and it’s a place where patient and patient families meet up every year. It just made sense to do a picnic and fundraiser. So, I am planning a one for the patients and patient families who normally meet up at Pig Jig. And since the folks at Pig Jig will match our donations up to $100,000, I am doing a small fundraiser and I am calling it “The Pig Jig Initiative.” NephCure is local to you. To learn more and get involved with your regional volunteer community, please click here.
Meet New York Regional Leader: Marlene Botta September 1, 2020 by Kylie Karley Marlene, her daughter, Jacqueline, and husband (L-R). Marlene Botta is a patient parent in the New York City area. Her daughter, Jacqueline, battles Nephrotic Syndrome. Marlene has done a tremendous amount of work at the state capital in Albany, even securing March 27th as “Nephrotic Syndrome Awareness Day” throughout New York every year. She’s lead the Long Island Walk multiple years and constantly fights for better treatments for those with Nephrotic Syndrome and FSGS. You can contact Marlene at nephcurenewyork@nephcurevolunteer.org. What’s your personal connection to NephCure? My daughter was diagnosed with Nephrotic Syndrome in 2016. NephCure has saved my life and my sanity. Without an outlet for my pain, I would have never gotten myself out of bed some mornings. It was a way for me to turn a horrific moment into triumph. Where do you focus your volunteer efforts with NephCure? My family and I do a lot of legislative relations in New York state. I speak to large groups about what NephCure does and try to get legislative initiatives to create awareness and raise funds. In addition to that, we do the Long Island NYC walk, which brings together our community and local families and creates a support system for all. What projects are you working on right now? I’m currently figuring out how to do my outreach in this post-Covid world. But, I always feel like I’m coming closer to creating a better life for those families afflicted by this insidious disease. NephCure is local to you. To learn more and get involved within your regional volunteer community, please click here.
Stop Proteinuria, NephCure Provides Resources to Broader Nephrology Community August 24, 2020 by Kylie Karley In recent years, we have seen Patient-Centered Outcomes, also known as Patient-Reported Outcomes (PROs), be implemented more regularly, specifically in the drug development and approval process. In fact, the Food and Drug Administration (FDA) created a Patient-Focused Drug Development Program specifically aimed at learning about how diseases impact patients’ lives and what an ideal treatment would look like from both patient and caregivers’ point of view. NephCure and our Voice of Patient volunteers continually invest their time to participate in various PRO projects, including Externally-Led Patient-Focused Drug Development Meetings with the FDA, patient and caregiver interviews, panels, and advisory boards with industry partners. These projects have led outside stakeholders towards developing deeper insight into patient priorities and have even played a part in making clinical trial protocols more patient-friendly. Through daily interactions with glomerular disease patients and caregivers, NephCure consistently sees one very concerning trend. Patients don’t always understand, and many nephrologists aren’t consistently explaining, the correlation between proteinuria and decreased kidney function. The article in the May 2020 edition of the Clinical Journal of the American Society of Nephrology, “Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers” clearly confirms this concern. The top 3 most important outcomes among patients include: Kidney function Mortality The need for dialysis or kidney transplant. However, patients’ consideration of proteinuria ranks twenty-third in priority. Over time, chronic proteinuria leads to kidney failure.1, 2 Proteinuria results from a dysfunction in the filtering units of the kidney. If a medication can treat that dysfunction, protein spilling into the urine will stop and the filtering units of the kidney (or glomeruli) will remain healthy. However, if protein continues to spill, the glomeruli will begin to scar, causing permanent damage and eventually a reduction in kidney function. In our professional capacity here at NephCure, the “home” for all individuals who are affected by primary protein-spilling kidney diseases, we have heard too many firsthand accounts of adult patients who have been diagnosed with glomerular disease and whose nephrologist does not treat the proteinuria. Instead, tragically, these patients’ labs are monitored once or twice a year, and they are told to come back when it’s time for dialysis and/or transplant. NephCure is working to change this practice by educating both the nephrology community and patient families that the number one treatment goal of any glomerular disease should be to stop proteinuria or reduce it as much as possible, which will in turn slow down the progression of the kidney disease and hopefully, in some cases, prevent the need for dialysis and/or transplant. To that end, we have developed a new patient-focused brochure aimed at educating newly-diagnosed patients and families about the importance of reducing proteinuria in order to maintain their kidney function. We are seeking a collaboration with the broader nephrology community to distribute these at point of care and help NephCure provide support and resources to the primary glomerular disease population. Kelly Helm, Assistant Director, Patient Advocacy If you are interested in supporting us in this endeavor, you can request patient materials here. Thank you for your interest in helping us reduce proteinuria, save kidneys, and save lives. Kelly Helm Assistant Director, Patient Advocacy 1 Troost JP, Trachtman H, Spino C, et al. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis [published online ahead of print, 2020 Jul 23]. Am J Kidney Dis. 2020;S0272-6386(20)30846-5. doi:10.1053/j.ajkd.2020.04.014 https://www.ajkd.org/article/S0272-6386(20)30846-5/fulltext 2 Troost JP, Trachtman H, Nachman PH, et al. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2018;13(3):414-421. doi:10.2215/CJN.04780517 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967666/
Protein-Spilling Kidney Diseases – A New Educational Primer Article August 14, 2020 by Lauren Eva Podocytopathies in focus Podocytopathies are kidney diseases in which injury to podocytes (key cells of the glomerulus, which is the filter in the kidney) results in proteinuria (loss of protein in the urine) or nephrotic syndrome (a condition characterized by swelling, usually in the extremities, and reduced albumin protein and increased lipids in the blood). This group of diseases is a major contributor to end-stage kidney disease worldwide. A new Primer article in the journal Nature Reviews Disease Primers, authored by a group of leading international experts, has just been published — endorsing the idea that these diseases should be described based on their underlying cause rather than their appearance on biopsy. A Primer article describes worldwide epidemiology, molecular mechanisms, diagnosis and management, and it provides a global and authoritative overview of research on these diseases, as well as of the challenges facing the research community as it strives towards a better understanding of this condition. Visual Summary of Podocytopathies (Protein-Spilling Kidney Diseases) Click on the image above to be taken through to the PrimeView on Podocytopathies. “Patients are often told they have ‘focal segmental glomerulosclerosis’ or ‘diffuse mesangial sclerosis’, but these are not diagnoses per se,” explains the Chief Editor of the journal, Clemens Thoma, DPhil, ORCID. “They are patterns that are revealed when the kidneys are biopsied.” The real challenges lie in understanding what causes these patterns and selecting the most effective and least toxic therapy for each patient, which is the goal of precision medicine. A broad spectrum of causes of podocyte injury can also produce relatively uniform clinical patterns (namely, proteinuria and nephrotic syndrome). “Because of this, these diseases manifest various degrees of proteinuria and risks of progressive kidney scarring,” explains Paola Romagnani, MD, PhD, lead author of the Primer. The Primer explains that distinct contributing factors with different relative contributions can combine to reach a threshold to induce podocyte injury and loss. Such factors include genetic predisposition, low birth weight, prematurity, increased body mass index and exposure to certain viruses and drugs. “Once we define the genetic factors and mechanisms underlying podocyte injury, then targeted personalized management of patients may become a reality,” says senior investigator Jeffrey Kopp, MD, a co-author of the Primer. All too often, current treatments are non-specific in that they address clinical manifestations rather than the underlying causes. “Recent work of ours and other groups suggest that patients with apparently identical ‘diseases’ do not respond similarly to treatments because they have different and unexpected genetic mutations as the underlying cause,” explains Professor Romagnani. “Novel diagnostic approaches involving nephrologists, geneticists and pathologists can identify these causes in more patients.” In the future, targeting specific forms and mechanisms of podocyte injury to promote podocyte repair and resilience may be possible using novel, precision medicine strategies. Professor Romagnani is optimistic for the future. “We hope the Primer will enhance understanding of the podocytopathies and will stimulate new approaches to research and therapeutics.” Read the Primer without access control here. The accompanying Primeview can be accessed here. Nature Reviews Disease Primers (@DiseasePrimers) is a Nature Research journal that was launched in 2015 to provide broad review articles on various health fields. The research described here is conducted in part by the Division of Intramural Research at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. The content in this release is the sole responsibility of the authors and does not necessarily represent the official views or imply endorsement of the National Institutes of Health.
An Inside Look: Vertex’s Study in APOL1-FSGS July 29, 2020 by Kylie Karley We recently sat down with Dr. Ogo Egbuna, Vertex Pharmaceutical’s clinical development lead for their clinical trial in APOL1-mediated focal segmental glomerulosclerosis (FSGS) to learn a bit more about their program and why it’s exciting for the disease community. Dr. Egbuna is a board-certified nephrologist with a deep interest in FSGS and he provided some insight into the importance of the trial and what potential participants should know if they’re interested. Dr. Ogo Egbuna The purpose of the study discussed below is to evaluate the safety, tolerability and effectiveness of an investigational medication in individuals with APOL1-mediated FSGS. The word “investigational” means this medication is not approved for use by the Food and Drug Administration (FDA) in the United States or other regulatory agencies in the UK, Europe or elsewhere. How is this drug different than other treatments currently in use for FSGS? As many of you may know, there are many different causes of FSGS. At Vertex, we’re focused on FSGS mediated by variants of the APOL1 gene. With our investigational small molecule treatment, we are aiming to target the underlying cause of disease by inhibiting the APOL1 pathway. Why is a drug for APOL1-mediated FSGS needed? A key part of our strategy at Vertex is to work on diseases where there is a high unmet need for treatment. The current treatments do not address the underlying cause of disease. Let’s assume that you are able to successfully recruit participants in this study and the drug proves to be effective. What is an estimated or typical timeline for when we could see this drug available on the market? Drug discovery and development is a long process, but we’re working as quickly as possible to do the things needed to determine whether this potential therapy has an acceptable risk/benefit profile for patients and if so, we’ll work with regulators to bring it to people who need it as soon as possible. At Vertex, we focus on serious diseases where we can have a transformative impact for patients, not just an incremental benefit. Rather than looking for problems we can solve with only the tools we’ve used before, we figure out the problems that need to be solved for the diseases we’re going after and invent the tools to potentially fix them. Who is this study for? We are excited to work with and grow our relationships with the FSGS community. This study is for adults of African or Caribbean descent (ages 18-60) with two APOL1 gene variants and biopsy confirmed FSGS. For more information on this study, please visit FSGSResearchStudy.com Do I have to live near a study site to participate? We are committed to designing our trial to be as easy for participants as possible, and we have taken the participant considerations into account each step of the way. With that in mind, we’re excited to incorporate telemedicine and participant choice into our clinical trial process. You do not need to live near a study site to participate in the Vertex APOL1-mediated FSGS study. Only your first screening visit needs to be in person; after that, all visits can be done from home, at the study site or a combination of the two. It is your choice. For home visits, a home health company will provide a nurse to visit your home to collect information and perform required tests. You’ll be able to complete a telemedicine phone call or video visit with the study doctor, and the study drug can be shipped right to your home. For visits at the study site, Vertex provides travel assistance that will support costs and arrangements. How will I know if I have an APOL1 gene variant? As part of the Vertex APOL1-mediated FSGS study, you will be tested for APOL1 gene variants. What does it mean if I test positive for the APOL1 gene variant? This means you have a genetic variant that increases your risk of developing kidney disease and accelerates the progression of kidney disease. Can I be in remission from proteinuria and still participate in the study? Patients who are in remission are not eligible for this study. Can I be on dialysis? Patients currently on dialysis are not eligible for this study. If I need a biopsy to participate in this study, will my insurance cover it? Would Vertex cover it? The study is enrolling participants with a previously confirmed FSGS diagnosis. This article was developed in partnership with Vertex Pharmaceuticals.
Nephrotic Syndrome Patients Tackle Kidney Disease as NephCure Interns July 7, 2020 by Kylie Karley When schools are no longer session, NephCure Kidney International opens its doors to fresh, new faces for internship opportunities. It’s standard protocol to not only give these students professional work experience, but to make sure they understand the struggles that come along with a Nephrotic Syndrome diagnosis. But this year, two of our interns already knew about these struggles firsthand. Both Peyton Azar and Beau Gent are patients diagnosed with rare, protein-spilling kidney diseases, and they’re both striving to make a difference in the lives of others. When Peyton Azar was eight years old, she began waking up with puffy, swollen eyes. At first, doctors believed the swelling was due to allergies, but various allergy treatments and the change of seasons failed to improve her symptoms. After a few months without relief, her doctors ordered a urine test; when protein was detected, they took swift action. “They took me to the children’s hospital in Pittsburgh the next morning, and then everything after that was kind of, I guess, my new life in a sense,” Peyton said. She was diagnosed with focal segmental glomerulosclerosis (FSGS), and since then has embarked on the long, up-and-down journey of living with a chronic kidney disease. “Since FSGS is more of a rare disease, I’ve kind of been a guinea pig for a lot of things. I’ve been in a lot of clinical studies and things of that nature,” she said, adding that her treatments have been on the intense side. She went into remission for a few years after her diagnosis but relapsed in seventh grade and underwent Prednisone infusions. The steroids helped, but not entirely; though her symptoms weren’t horrible, she wasn’t necessarily in remission. Then, when Peyton was 15, her kidneys began to fail. She went on dialysis, and in July 2015, the summer after her sophomore year of high school, she received a kidney transplant, with a kidney from a special living donor: her mother. But soon after the transplant, her kidneys unfortunately failed again—the FSGS was attacking once more. In yet another effort to combat the disease, Peyton began plasmapheresis, which helped her move into remission after a few months of treatment. In the four and a half years since then, she hasn’t experienced a single relapse. “I definitely don’t feel as normal as the average person would,” she expressed. “I definitely get fatigued easier, and sometimes my transplant site will hurt. I also get migraines a lot and have stomach issues from my medications. So, it’s definitely not normal, but it’s a lot better than pre-transplant.” Peyton is a rising senior at West Virginia University, and explains that within the last year, she has developed a much clearer picture of the career path she wants to take: working with a health organization, ideally in a patient advocacy role. “I would love to be a part of something that makes a difference,” she said, adding although she’s hoping to work in the healthcare field, she’s also open to joining a nonprofit with a focus other than healthcare—just as long as she’s helping people. Peyton refuses to let her disease dictate her life or dampen her aspirations. “I feel like so many people with health issues think ‘Why me? Why did it happen? Why do I have this?’” she said. “But I think a big one for me is ‘Okay, I have this. What can I do with it?’ I don’t want to just sit down and take it, I guess. I want it turned to something positive and have it strengthen my character.” While Peyton is interning with NephCure’s Department of Research and Engagement, Beau Gent, another Nephrotic Syndrome patient and summer intern, is working with the Community Development team. A rising junior at Regis University in Denver, Beau’s kidney health journey has been a winding one. At 13 years old, Beau was diagnosed with lupus. Although his health was relatively stable throughout his high school career, he experienced harsh flare-ups during his freshmen year of college. His doctor ordered blood work and found a concerning creatinine level. Shortly after, he was hospitalized and received a new diagnosis. “I was then diagnosed with lupus nephritis because my lupus had then started attacking my kidneys, and then from there it kept on progressing,” Beau explained. He was 18 years old at the time. “At one point they thought that they were going to be able to salvage my kidneys,” he said, describing how he underwent a multitude of immunosuppressant treatments, including a round of steroids and then chemotherapy—neither treatment helped. After his freshmen year, with little improvement, Beau received a third diagnosis: end-stage renal disease. “I haven’t been through this whole kidney journey as long as many other people, but it came extremely fast, and it was tough,” he explained. In July of 2019, less than a year after he was diagnosed with lupus nephritis, Beau started dialysis. “I spent my entire sophomore year on dialysis, which was a time and a half, to say the least. I would go to classes in the morning, and then in the afternoon I would go to dialysis. So, I’d start my day around 7:00 in the morning and I’d end my day at 8:00 or 9:00 at night,” he said. “It wasn’t ideal, but it was a necessary thing, and thankfully I was able to make it work.” In April 2020, Beau underwent a kidney transplant, and, like Peyton, received a kidney from one of his parents. Beau’s living donor was his father, and since the transplant, he’s improved tremendously. Though his doctors haven’t specifically declared he’s in remission, the results of his blood work and other appointments have been encouraging. “I’ve been leaps and bounds better,” he said. “I feel absolutely amazing.” For Beau, who enjoys weightlifting, the hardest part about dialysis was being unable to gain any weight or muscle mass. “Once I got on the dialysis and they were taking all that water weight off, I was like a string bean,” he laughed. Six weeks after his transplant, he was able to begin lifting weights and hiking again, which he describes as ‘a huge blessing.’ Beau’s intern position with NephCure isn’t the first time he’s been involved with the organization. Last year, his mother entered an essay writing contest sponsored by NephCure, and she and Beau were selected to travel with the team to lobby government officials in Washington, D.C. Like Peyton, Beau also wants to dedicate his career to helping others. His goal is to become a physician’s assistant, specifically in the pediatric field, and he says he might even want to go into nephrology. “I’ve gotten to talk to a lot of amazing healthcare professionals, and I’ve gotten to talk to some not so amazing healthcare professionals, and kind of learn things that I would like to change in the system, and learn things that I would like to keep in the system,” Beau said. “I think that that is definitely an interesting perspective that you can have as a patient kind of going into a healthcare profession yourself, because you know it firsthand.” Though he was quickly forced into a life of serious kidney disease on top of an autoimmune disorder, Beau doesn’t let his illnesses define him. “My goal has always been to make people think that I’ve never been sick,” he said. “I want to work ten times harder than the healthiest person around, being that it’s okay for my health personally.” Beau and his mother have a motto they live by to help push them through the hard times: “no wasted days.” Living with chronic illnesses means every day has the potential to be a challenge; Beau makes a conscious effort to truly appreciate the days that aren’t so tough. “If you’re given a day where you don’t feel absolutely terrible and you can do a little bit, or you can push yourself a little bit more, take advantage of it,” he said. “Because you don’t know if the next day you’re going to feel terrible again and can’t get out of bed.” Both Beau and Peyton have already greatly contributed to the team. Their presence is an appreciated reminder of the strength and resiliency Nephrotic Syndrome patients possess, and NephCure is looking forward to their continued collaboration.
Nephrotic Syndrome and COVID-19 – Updated Guidelines June 25, 2020 by Kylie Karley While the past few months have brought a great deal of confusion, pain, and discomfort to the entire world, we understand the thirst for information is just as prevalent now as it was at the start of the COVID-19 pandemic. As new research is coming out and guidelines are seemingly changing every day, NephCure is here to help you and other patients with protein-spilling kidney diseases navigate the unknown. We continue to advise you to consult with your physician to design your own protection plan, as every patient’s situation is unique. No matter your age, if you have chronic kidney disease at any stage or have received an organ transplant, the CDC has clearly outlined and our NephCure Specialists agree that you are at an increased risk for complications from the COVID-19 virus. We recognize that while your physical health is important, your mental, social, and financial health are also a priority. We encourage you to talk to your doctor, family, and support system to devise a plan you feel comfortable with as you decide when and how to re-enter society. In the words of Dr. Anthony Fauci, “If it looks like you’re overreacting, you’re probably doing the right thing.” Ultimately, until a vaccine is found, we urge you to follow all precautionary steps recommended by the CDC to decrease your chance of getting COVID-19 infection. We are in regular communication with our NephCure Specialists to help find the answers you need. We will keep you updated as we receive new information in the coming weeks and months. As you develop your protection plan, here are some key points to remember: Consult with your personal nephrologist and family to create a plan that is right for you. Review the most current guidelines from the CDC. Your risk may vary depending on the community spread within your region. Search for your county using this map and check with your local health department for information relevant to your location. This statement was prepared with input from NephCure Specialists: Ambarish Athavale, MBBS, MD Lawrence Holzman, MD Elaine Kamil, MD Ali Poyan Mehr, MD
NephCure Kidney International Promotes Lauren Lee to Executive Vice President, Stakeholder Engagement June 23, 2020 by Kylie Karley KING OF PRUSSIA, PA (June 23, 2020) – NephCure Kidney International® announced today the promotion of Lauren Lee to Executive Vice President, Stakeholder Engagement, effective immediately. In her new role, Lee will oversee the departments of Research & Engagement, Community Development, and Operations. Lee will continue to report to NephCure Chief Executive Officer Joshua Tarnoff. Lauren Lee, Executive Vice President, Stakeholder Engagement In her prior role as Chief Research Officer, Lee transformed the Department of Research & Engagement to reach a broad array of stakeholders, including patients, healthcare providers, researchers, government entities, biopharmaceutical companies, and other like-minded NGOs. She recently led the mission-critical Gateway Initiative that now involves nearly 30 primary glomerular kidney disease clinical trials across the globe and balances a wide number of collaborators. To date, no company has left the space due to recruiting difficulties: the hallmark charge and success gauge of the initiative. “From day one, Lauren has displayed incredible compassion for patients and tireless dedication to our mission while handling multiple consuming programs,” Tarnoff said. “Her strong leadership and strategic vision in adapting to evolving environmental demands and driving key programmatic successes made her the clear choice both internally and externally when considering candidates for this large and critical new senior level role. I’m thrilled to announce her promotion at a time when our patient community is in urgent need of additional support due to COVID-19 and an influx of clinical research opportunities.” Lee has worked for NephCure since 2013, starting as Director of Grassroots Operations before spending 6 years directing the Research & Engagement Department. For many years, she led NephCure’s efforts to build a nation-wide network of patient families, clinicians, and researchers, over the years traveling to nearly every major and minor city within the NephCure community. More recently, she has played a key role in effectively steering NephCure into a powerful clinical research facilitator and collaborator within the glomerular kidney disease space. “It is truly a privilege to be part of an outstanding organization like NephCure,” Lee shared. “We have only just begun to hit our stride in making a material difference in the lives of the patients we serve through meaningful initiatives like Gateway, the NephCure Specialist directory, and our Regional Volunteer Communities. In this new role, I hope to continue the momentum with a keen focus on mobilizing all stakeholders around our mission of bringing new treatments to patients.” Lee earned a Bachelor of Arts in Anthropology and French from Carleton University in Ontario, Canada and a Master of Arts in Museum Studies from the State University of New York at Oneonta. She will remain based in the Philadelphia area. About NephCure Kidney International NephCure Kidney International’s mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now nearly 30 interventional drug trials for primary glomerular kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity. www.NephCure.org Contact: Lauren Eva 610-540-0186 x21 Lauren.Eva@NephCure.org
Our commitment to our communities of color. June 10, 2020 by Lauren Eva Enough. We are deeply horrified by the recent violent deaths of George Floyd in Minnesota and Breonna Taylor in Kentucky. They are the latest in a vast chain of Black men, women, and children in the United States whose lives have been tragically and wrongfully cut short. Their lives mattered. We stand in solidarity with those fighting for justice, peace, and equity for Black people and other communities of color in this country. Systemic racism and deeply entrenched inequalities have plagued our country since even before its founding. Our healthcare system continues to deny equitable access to research and care that could significantly improve the lives of Black people and other people of color at all walks of life.1, 2, 3, 4, 5 At NephCure, we are focused on providing support and education to all who are affected by chronic, rare, and progressive protein-spilling kidney diseases, in addition to pushing forward research to better treat and cure these diseases. Black Americans are disproportionately affected by chronic kidney disease, and uniquely affected by an aggressive form of a protein-spilling kidney disease called Focal Segmental Glomerulosclerosis (FSGS).6, 7 Working to improve the options and availability of treatments for Black individuals affected by kidney disease falls squarely within the scope of our organization. NephCure serves ALL people who are affected by protein-spilling kidney diseases, but we know we can do better for our communities of color. We have been working with some collaborators over the past few months on a Health Equity project, focused on increasing diversity in this field, and we’re excited to share more about that soon. But we recognize that this moment is not about us. With that in mind, we are providing space and time throughout this month (and beyond) specifically aimed at highlighting Black voices within our community. There is a great deal of work to be done, and we are dedicated to learning, growing, and constantly improving. If you are so inclined, we welcome your feedback on how we’re doing in this regard. We are not so audacious to expect that we can end the consequences of systemic inequities that have negatively shaped life for Black people in the United States for hundreds of years. But we believe we can make change in our community. And we will. 1 Hamel LM et al., (2016). Barriers to clinical trial enrollment in racial and ethnic minority patients with Cancer. Cancer Control. 2016 Oct; 23(4): 327–337. DOI: 10.1177/107327481602300404 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131730/ 2US Food and Drug Administration. (2017, February 13). Drug Trials Snapshots Summary Report (2015 and 2016) https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-summary-report-2015-and-2016 3D. K. Ginther et al., (2011). Race, ethnicity, and NIH research awards. Science. 333, 1015–1019 (2011). DOI: 10.1126/science.1196783 https://science.sciencemag.org/content/333/6045/1015.full 4The Commonwealth Fund. (2008, April 1). Do Primary Care Physicians Treating Minority Patients Report Problems Delivering High-Quality Care? https://www.commonwealthfund.org/publications/journal-article/2008/apr/do-primary-care-physicians-treating-minority-patients-report 5Hayanga, AJ et al., (2009). Residential Segregation and Access to Surgical Care by Minority Populations in US Counties. Journal of the American College of Surgeons, 208(6), 1017-1022. DOI: https://doi.org/10.1016/j.jamcollsurg.2009.01.047 https://www.journalacs.org/article/S1072-7515%2809%2900207-5/abstract 6National Institute of Diabetes and Digestive and Kidney Diseases. Race, Ethnicity, & Kidney Disease. Retrieved June 8, 2020, from https://www.niddk.nih.gov/health-information/kidney-disease/race-ethnicity 7Rosenberg AZ, Kopp JB (2017). Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2017;12:502–17.doi:10.2215/CJN.05960616 https://cjasn.asnjournals.org/content/12/3/502
Finding the Beauty in Kidney Disease: Keyaira Sanders’ Story June 8, 2020 by Kylie Karley “When I was 10 years old, I remember being at a family gathering and feeling absolutely horrible. For the life of me, I couldn’t figure out why I wasn’t feeling well, but I just wanted to feel better. The first sign that I noticed as a ten-year-old little girl was the puffiness around my eyes. My parents started treatment with allergy medications for approximately a week, but as the days progressed, I began to feel worse. I noticed swelling all over my body, and I also noticed that I couldn’t urinate as much as I usually would. My mother then took me to my pediatrician; I still can picture the puzzled look upon her face when she examined me. She explained to my mother that this was far beyond allergies, and that she should take me to Le Bonheur Children’s Hospital in downtown Memphis. After seemingly endless tests and blood and urine samples, one of the pediatric nephrologists came in and explained I had Nephrotic Syndrome. He told us that this was a very rare disease and that I would need a kidney biopsy to determine what form I had. As a little girl, I had no clue what any of this meant. The doctor made sure to immediately start me on a high dose of Prednisone (steroids) and Lasix (water pills) to help my kidneys get into remission and drain some of the fluid out of my body. The Lasix worked—I was up the majority of the night urinating! The next day, I was scheduled to have my kidney biopsy. I was terrified—all I could think of was the huge needle going into my back. As the time drew nearer, my heart felt as if it was about to explode through my chest. Teddy bear in hand, I was taken back to the operating room. The doctor told me to relax and that I was going to be given some “happy medicine.” The next thing I knew, I woke up back in my hospital room. I was in a bit of pain, but it wasn’t as bad as I had imagined. After being in the hospital for almost five days, I was still receiving steroids daily. I began to notice my appetite increasing, and I later learned that this was one of the common side effects of Prednisone. A few more days went by, we discovered I had Minimal Change Disease. Nephrotic Syndrome can be a very tricky disease, because everyone is different, and we all respond to medications differently. For me, the steroids were a go! I was able to take the high-dose steroids partnered with blood pressure medications (due to the steroids increasing my blood pressure as another side effect) and Lasix for the fluid. After being in the hospital for a month and a half, I was finally able to go home and continue my treatment. I was so happy to finally be going home and going back to normal. Little did I know, this was only the beginning. Fast forward to my sophomore year of high school. I remember being at after school band practice and being in so much pain. My upper back was hurting me on the left side, and I was very short of breath. I managed to get through the entire practice, but I knew something wasn’t right. I got home that night and I didn’t even want to eat; I sat straight up the entire night, just breathing. I remember crying all alone, thinking “I don’t know what this is, but I need to seek some kind of help.” My mom took me to the emergency room the following day, and they told me that I had pneumonia. They didn’t check anything concerning my disease at all and sent me home with absolutely nothing. When we got home, I still couldn’t even hold down water! My mother had had enough and called my father from out of town to take me back to the hospital in Memphis for another opinion. They rushed me to the back and began testing immediately. One test I couldn’t even do, because it required me to lie down flat, and I was in too much pain. I cried all the way there and while we were there. I really broke down when a team of doctors came swarming into the room, asking my father to leave and saying that they had to start treatment right away because my case was very severe. I was only 15 at the time. I remember hearing the words ‘pulmonary embolism.’ I was puzzled, but later found out that I had a blood clot in my left lung. They had to begin treatment right away because this was life-threatening. I was placed on a ventilator for about a week, because one day I was trying to get up and blacked out. There’s not much more that I remember about that experience, but the doctors told my parents that I was very lucky to be alive. Looking back, I am beyond grateful and I understand my purpose. More time has passed. I am now 22 years old, and I look back at all of the experiences that I have had with this disease—the good and the bad. It may sound crazy, but I wouldn’t change anything that has happened to me. Having Nephrotic Syndrome has not only helped me to grow into the person I am, but it’s also helped me to appreciate life. I know from experience this disease is NOT easy at all; it can be painful and take a huge toll on you and those around you mentally, physically and emotionally. Often times people assume that just because you may be in remission or back to normal physically, you must also be okay mentally and emotionally. But I’ve battled with depression because I felt as if I wasn’t normal. I’ve had to miss tons of school days, my parents have had to miss work, I’ve had to try different medications through trial-and-error, I’ve had to give myself blood-thinner injections, and recently I’ve had to start Rituxan infusions—this has been a rollercoaster. Living with this disease is very hard because you always have that “what if,” or that fear that you’ll relapse and have to go through it all again. It’s a shame to say, but I’ve had doctors not even know how to treat me properly, and this is one of many issues that needs to be highlighted. This is why I am taking a stand: to be a voice to help others who may not feel comfortable sharing their stories. Hopefully me taking this stand inspires so many others to share their stories as well. I hope whoever reads this finds some kind of positive message and holds on to that for hope. We are all in this together! A saying that I came up with myself and live by is this: “While we all have something ugly that we go through, we must find the beauty in it and allow it to shape us into the person we are destined to be in life.” So, no matter what you may be going through, just remember that we all have something ugly, but it’s up to us to bring out the beauty. What’s the beauty in your story?” – written by Keyaira Sanders